Cisplatin-induced nephrotoxicity and targets of nephroprotection: An update

Archives of Toxicology

Volumn 86, Issue 8, 2012, Pages 1233-1250

  Dos Santos, Neife Aparecida Guinaim ^a   Rodrigues, Maria Augusta Carvalho ^a   Martins, Nadia Maria ^a   Dos Santos, Antonio Cardozo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Apoptosis; Cisplatin; Mitochondria; Molecular mechanisms; Nephroprotection; Nephrotoxicity; Oxidative stress

Indexed keywords

ACIVICIN; ALLOPURINOL; ALPHA TOCOPHEROL; AMINOOXYACETIC ACID; ANTIOXIDANT; ASCORBIC ACID; CAFFEIC ACID PHENETHYL ESTER; CAPTOPRIL; CARVEDILOL; CASPASE 8; CIMETIDINE; CISPLATIN; DIETHYLDITHIOCARBAMIC ACID; DIMESNA; EBSELEN; FUROSEMIDE; GLUTATHIONE; IMATINIB; LYCOPENE; MANNITOL; METHIONINE; NARINGENIN; NORPHENAZONE; QUERCETIN; RESVERATROL; RETINOL; SODIUM CHLORIDE; SODIUM THIOSULFATE; THIOL DERIVATIVE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; ENDOPLASMIC RETICULUM; HUMAN; INFLAMMATION; KIDNEY BLOOD FLOW; MITOCHONDRION; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CISPLATIN; CYTOPROTECTION; HUMANS; KIDNEY; KIDNEY DISEASES; PROTECTIVE AGENTS; SIGNAL TRANSDUCTION;

EID: 84866051499     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-012-0821-7     Document Type: Review

References (206)

1. Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26:61-66 (Pubitemid 32124712)
2. Ajith TA, Abhishek G, Roshny D, Sudheesh NP (2009) Cosupplementation of single and multi doses of vitamins C and E ameliorates cisplatin-induced acute renal failure in mice. Exp Toxicol Pathol 61:565-571
3. Ali BH, Al Moundhri MS (2006) Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 44:1173-1183
4. Antunes LM, Darin JD, Bianchi MD (2000) Protective effects of vitamin c against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res 41:405-411
5. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460-464 (Pubitemid 37176691)
6. Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A (2005) Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 212:116-123 (Pubitemid 40981968)
7. Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH (2005) Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci 76:2125-2135 (Pubitemid 40249370)
8. Bae EH, Lee J, Ma SK, Kim IJ, Frokiaer J, Nielsen S, Kim SY, Kim SW (2009) Alpha-lipoic acid prevents cisplatin-induced acute kidney injury in rats. Nephrol Dial Transplant 24:2692-2700
9. Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK (2003) Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 142:178-186 (Pubitemid 37260471)
10. Bajorin DF, Bosl GJ, Alcock NW, Niedzwiecki D, Gallina E, Shurgot B (1986) Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res 46:5969-5972 (Pubitemid 17178013)
11. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV (1998) Role of cytochrome P-450 as a source of catalytic iron in cisplatininduced nephrotoxicity. Kidney Int 54:1562-1569 (Pubitemid 28502898)
12. Barnes PJ (1997) Nuclear factor-kappa B. Int J Biochem Cell Biol 29:867-870
13. Bauer MK, Vogt M, Los M, Siegel J, Wesselborg S, Schulze-Osthoff K (1998) Role of reactive oxygen intermediates in activationinduced CD95 (APO-1/Fas) ligand expression. J Biol Chem 273:8048-8055 (Pubitemid 28168856)
14. Beehler CJ, Ely ME, Rutledge KS, Simchuk ML, Reiss OK, Shanley PF, Repine JE (1994) Toxic effects of dimethylthiourea in rats. J Lab Clin Med 123:73-80 (Pubitemid 2048475)
15. Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT (2005) Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebocontrolled trial. J Am Soc Nephrol 16:452-458 (Pubitemid 41725141)
16. Beyaert R, Fiers W (1994) Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. FEBS Lett 340:9-16
17. Block KI, Gyllenhaal C (2005) Commentary: the pharmacological antioxidant amifostine-implications of recent research for integrative cancer care. Integr Cancer Ther 4:329-351 (Pubitemid 41698182)
18. Bonegio R, Lieberthal W(2002) Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 11:301-308 (Pubitemid 34496778)
19. Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer FH, Pinedo HM, van der Vijgh WJ (2002) BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. Eur J Cancer 38:1148-1156 (Pubitemid 34468022)
20. Brouwers EE, Huitema AD, Schellens JH, Beijnen JH (2008) The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry. Anticancer Drugs 19:621-630
21. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA (2011) Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 14:22-34
22. Burns TF, El-Deiry WS (1999) The p53 pathway and apoptosis. J Cell Physiol 181:231-239 (Pubitemid 29463638)
23. Campbell NP, Kindler HL (2011) Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 32:102-110
24. Campbell MT, Dagher P, Hile KL, Zhang H, Meldrum DR, Rink RC, Meldrum KK (2008) Tumor necrosis factor-alpha induces intrinsic apoptotic signaling during renal obstruction through truncated bid activation. J Urol 180:2694-2700
25. Candelaria M, Garcia-Arias A, Cetina L, Duenas-Gonzalez A (2006) Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol 1:15
26. Caro AA, Cederbaum AI (2004) Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 44:27-42 (Pubitemid 38263832)
27. Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M (2002) L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 405:55-64 (Pubitemid 35026166)
28. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167:1477-1484 (Pubitemid 41713303)
29. Cilenti L, Kyriazis GA, Soundarapandian MM, Stratico V, Yerkes A, Park KM, Sheridan AM, Alnemri ES, Bonventre JV, Zervos AS (2005) Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol 288:F371-F379 (Pubitemid 40105396)
30. Cohen SM, Lippard SJ (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93-130 (Pubitemid 33804642)
31. Conklin KA (2004) Cancer chemotherapy and antioxidants. J Nutr 134:3201S-3204S (Pubitemid 39470116)
32. Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50:147-158 (Pubitemid 23275196)
33. Cullen KJ, Yang Z, Schumaker L, Guo Z (2007) Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39:43-50 (Pubitemid 46877172)
34. Cummings BS, McHowat J, Schnellmann RG (2004) Role of an endoplasmic reticulum Ca2+ -independent phospholipase A2 in cisplatin-induced renal cell apoptosis. J Pharmacol Exp Ther 308:921-928 (Pubitemid 38263966)
35. Cvitkovic E (1998) Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev 24:265-281 (Pubitemid 28488281)
36. Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N, Kroemer G (2000a) Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett 476:118-123 (Pubitemid 30410801)
37. Daugas E, Susin SA, Zamzami N, Ferri KF, Irinopoulou T, Larochette N, Prevost MC, Leber B, Andrews D, Penninger J, Kroemer G (2000b) Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J 14:729-739 (Pubitemid 30198571)
38. Dillioglugil MO, Maral Kir H, Gulkac MD, Ozon Kanli A, Ozdogan HK, Acar O, Dillioglugil O (2005) Protective effects of increasing vitamin E and a doses on cisplatin-induced oxidative damage to kidney tissue in rats. Urol Int 75:340-344 (Pubitemid 41752584)
39. Do Amaral CL, Francescato HD, Coimbra TM, Costa RS, Darin JD, Antunes LM, Bianchi MdeL (2008) Resveratrol attenuates cisplatin- induced nephrotoxicity in rats. Arch Toxicol 82:363-370
40. Dong G, Luo J, Kumar V, Dong Z (2009) Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Renal Physiol 298:F293-F300
41. dos Santos OF, Boim MA, Barros EJ, Pirotzky E, Braquet P, Schor N (1991a) Effect of platelet-activating factor antagonist BN 52063 on the nephrotoxicity of cisplatin. Lipids 26:1324-1328
42. Dos Santos OF, Boim MA, Barros EJ, Schor N (1991b) Role of platelet activating factor in gentamicin and cisplatin nephrotoxicity. Kidney Int 40:742-747
43. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33-42
44. Dumas M, de Gislain C, d'Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, Autissier N (1990) Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis- diamminedichloroplatinum(II). Cancer Chemother Pharmacol 26:278-282 (Pubitemid 20211114)
45. Eastman A (1999) The mechanism of action of cisplatin: from adducts to apoptosis. I. In: Lippert B (ed) Cisplatin: chemistry and biochemistry of a leading anticancer drug. Wiley, New York, pp 111-135
46. El Sabbahy M, Vaidya VS (2011) Ischemic kidney injury and mechanisms of tissue repair. Wiley Interdiscip Rev Syst Biol Med 3:606-618
47. El-Sayed el SM, Abd-Ellah MF, Attia SM (2008) Protective effect of captopril against cisplatin-induced nephrotoxicity in rats. Pak J Pharm Sci 21:255-261
48. Enoksson M, Robertson JD, Gogvadze V, Bu P, Kropotov A, Zhivotovsky B, Orrenius S (2004) Caspase-2 permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids. J Biol Chem 279:49575-49578 (Pubitemid 39577759)
49. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL (2004) Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int 66:2202-2213 (Pubitemid 41115283)
50. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322:8-15 (Pubitemid 46956357)
51. Francescato HD, Coimbra TM, Costa RS, Bianchi MdeL (2004) Protective effect of quercetin on the evolution of cisplatininduced acute tubular necrosis. Kidney Blood Press Res 27:148-158 (Pubitemid 39140424)
52. Frick GA, Ballentine R, Driever CW, Kramer WG (1979) Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum (II) administered with hydration and mannitol diuresis. Cancer Treat Rep 63:13-16 (Pubitemid 9152660)
53. Gale GR, Morris CR, Atkins LM, Smith AB (1973) Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res 33:813-818
54. Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW (1990) Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol 10:353-365
55. Gately DP, Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67:1171-1176 (Pubitemid 23172848)
56. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK (2010) First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5:260-274
57. Goldstein RS, Mayor GH (1983) Minireview. The nephrotoxicity of cisplatin. Life Sci 32:685-690
58. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1977) The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362-1371 (Pubitemid 8108286)
59. Gonzalez VM, Fuertes MA, Alonso C, Perez JM (2001) Is cisplatininduced cell death always produced by apoptosis? Mol Pharmacol 59:657-663 (Pubitemid 32273993)
60. Goossens V, Grooten J, De Vos K, FiersW (1995) Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA 92:8115-8119
61. Gordon JA, Gattone VH 2nd (1986) Mitochondrial alterations in cisplatin-induced acute renal failure. Am J Physiol 250:F991-F998
62. Guastalla JP, Vermorken JB, Wils JA, George M, Scotto V, Nooij M, ten Bokkel Huinnink WW, Dalesio O, Renard J (1994) Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy-a phase II study of the EORTC Gynaecological Cancer Cooperative Group. Eur J Cancer 30A:45-49 (Pubitemid 24058088)
63. Han X, Yue J, Chesney RW (2009) Functional TauT protects against acute kidney injury. J Am Soc Nephrol 20:1323-1332
64. Hanigan MH, Devarajan P (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther 1:47-61
65. Hanigan MH, Gallagher BC, Taylor PT Jr, Large MK (1994) Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res 54:5925-5929
66. Hanigan MH, Lykissa ED, Townsend DM, Ou CN, Barrios R, Lieberman MW (2001) Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol 159:1889-1894 (Pubitemid 33062530)
67. Hanigan MH, Deng M, Zhang L, Taylor PT Jr, Lapus MG (2005) Stress response inhibits the nephrotoxicity of cisplatin. Am J Physiol Renal Physiol 288:F125-F132 (Pubitemid 40038684)
68. Hannemann J, Duwe J, Baumann K (1991) Iron- and ascorbic acidinduced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds. Cancer Chemother Pharmacol 28:427-433
69. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM (1998) Modulation of platinuminduced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin Oncol 25:584-599 (Pubitemid 28478065)
70. Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q, Kochat H, Petluru PN, Parker AR (2010) Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol 65:941-951
71. Hausheer FH, Ding D, Shanmugarajah D, Leverett BD, Huang Q, Chen X, Kochat H, Ayala PY, Petluru PN, Parker AR (2011a) Accumulation of BNP7787 in human renal proximal tubule cells. J Pharm Sci 100:3977-3984
72. Hausheer FH, Parker AR, Petluru PN, Jair KW, Chen S, Huang Q, Chen X, Ayala PY, Shanmugarajah D, Kochat H (2011b) Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N. Cancer Chemother Pharmacol 67:381-391
73. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372-1381 (Pubitemid 8108287)
74. Heidemann HT, Muller S, Mertins L, Stepan G, Hoffmann K, Ohnhaus EE (1989) Effect of aminophylline on cisplatin nephrotoxicity in the rat. Br J Pharmacol 97:313-318 (Pubitemid 19142732)
75. Heinecke JW, Kawamura M, Suzuki L, Chait A (1993) Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res 34:2051-2061 (Pubitemid 24000954)
76. Helm CW, States JC (2009) Enhancing the efficacy of cisplatin in ovarian cancer treatment-could arsenic have a role. J Ovarian Res 2:2
77. Hofmann J, Fiebig HH, Winterhalter BR, Berger DP, Grunicke H (1990) Enhancement of the antiproliferative activity of cisdiamminedichloroplatinum (II) by quercetin. Int J Cancer 45:536-539 (Pubitemid 20087205)
78. Hye Khan MA, Abdul Sattar M, Abdullah NA, Johns EJ (2007) Cisplatin-induced nephrotoxicity causes altered renal hemodynamics in Wistar Kyoto and spontaneously hypertensive rats: role of augmented renal alpha-adrenergic responsiveness. Exp Toxicol Pathol 59:253-260 (Pubitemid 350030444)
79. Iguchi T, Nishikawa M, Chang B, Muroya O, Sato EF, Nakatani T, Inoue M (2004) Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney. Free Radic Res 38:333-341 (Pubitemid 38455857)
80. Ikeda S, Fukuzaki A, Kaneto H, Ishidoya S, Orikasa S (1999) Role of protein kinase C in cisplatin nephrotoxicity. Int J Urol 6:245-250 (Pubitemid 29233809)
81. Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298-14302 (Pubitemid 35257666)
82. Ismaili N, Amzerin M, Elmajjaoui S, Droz JP, Flechon A, Errihani H (2011a) The role of chemotherapy in the management of bladder cancer. Prog Urol 21:369-382
83. Ismaili N, Amzerin M, Flechon A (2011b) Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol 4:35
84. Jackson AM, Rose BD, Graff LG, Jacobs JB, Schwartz JH, Strauss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG (1984) Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 101:41-44 (Pubitemid 14088065)
85. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498
86. Jia Z, Wang N, Aoyagi T, Wang H, Liu H, Yang T (2011) Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis. Kidney Int 79:77-88
87. Jiang M, Dong Z (2008) Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 327:300-307
88. Jiang M, Yi X, Hsu S, Wang CY, Dong Z (2004) Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 287:F1140- F1147 (Pubitemid 39507222)
89. Jiang M, Wei Q, Wang J, Du Q, Yu J, Zhang L, Dong Z (2006) Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25:4056-4066 (Pubitemid 44024868)
90. Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z (2007) Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73:1499-1510 (Pubitemid 46452592)
91. Johnson AL, Ratajczak C, Haugen MJ, Liu HK, Woods DC (2007) Tumor necrosis factor-related apoptosis inducing ligand expression and activity in hen granulosa cells. Reproduction 133:609-616 (Pubitemid 46671865)
92. Jones MM, Basinger MA, Field L, Holscher MA (1991) Coadministration of dimethyl sulfoxide reduces cisplatin nephrotoxicity. Anticancer Res 11:1939-1942
93. Kachadourian R, Leitner HM, Day BJ (2007) Selected flavonoids potentiate the toxicity of cisplatin in human lung adenocarcinoma cells: a role for glutathione depletion. Int J Oncol 31:161-168
94. Kadikoylu G, Bolaman Z, Demir S, Balkaya M, Akalin N, Enli Y (2004) The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol 23:29-34 (Pubitemid 38263155)
95. Katsuda H, Yamashita M, Katsura H, Yu J, Waki Y, Nagata N, Sai Y, Miyamoto K (2010) Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 33:1867-1871
96. Katzenstein HM, Chang KW, Krailo M, Chen Z, Finegold MJ, Rowland J, Reynolds M, Pappo A, London WB, Malogolowkin M (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 115:5828-5835
97. Kaushal GP, Kaushal V, Hong X, Shah SV (2001) Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 60:1726-1736 (Pubitemid 32999977)
98. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112 (Pubitemid 26230113)
99. Khan AH, Sattar MA, Abdullah NA, Johns EJ (2007) Influence of cisplatin-induced renal failure on the alpha(1)-adrenoceptor subtype causing vasoconstriction in the kidney of the rat. Eur J Pharmacol 569:110-118 (Pubitemid 47175868)
100. Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24:19-38
101. Koyner JL, Sher Ali R, Murray PT (2008) Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury? Nephron Exp Nephrol 109:e109-e117
102. Kruidering M, Maasdam DH, Prins FA, de Heer E, Mulder GJ, Nagelkerke JF (1994) Evaluation of nephrotoxicity in vitro using a suspension of highly purified porcine proximal tubular cells and characterization of the cells in primary culture. Exp Nephrol 2:324-344
103. Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF (1997) Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 280:638-649 (Pubitemid 27171323)
104. Kuhar M, Sen S, Singh N (2006) Role of mitochondria in quercetinenhanced chemotherapeutic response in human non-small cell lung carcinoma H-520 cells. Anticancer Res 26:1297-1303
105. Kuhlmann MK, Burkhardt G, Kohler H (1997) Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12:2478-2480 (Pubitemid 27520658)
106. Lau AH (1999) Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int 56:1295-1298 (Pubitemid 29451234)
107. Laughton MJ, Halliwell B, Evans PJ, Hoult JR (1989) Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochem Pharmacol 38:2859-2865 (Pubitemid 19219848)
108. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61:903-909
109. Lee RH, Song JM, Park MY, Kang SK, Kim YK, Jung JS (2001) Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol 62:1013-1023
110. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Park SK (2006) Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 21:2096-2105 (Pubitemid 44295034)
111. Lehane D, Winston A, Gray R, Daskal Y (1979) The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cisplatinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys 5:1393-1399 (Pubitemid 10159446)
112. Li G, Sha SH, Zotova E, Arezzo J, Van de Water T, Schacht J (2002) Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 82:585-596 (Pubitemid 34522371)
113. Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V (2010) Pituitary adenylate cyclase-activating polypeptide ameliorates cisplatin-induced acute kidney injury. Peptides 31:592-602
114. Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V (2011) Pituitary adenylate cyclase-activating polypeptide prevents cisplatin-induced renal failure. J Mol Neurosci 43:58-66
115. Lieberthal W, Triaca V, Levine J (1996) Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 270:F700-F708
116. Lieberthal W, Menza SA, Levine JS (1998) Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol 274:F315-F327
117. Lin X, Okuda T, Holzer A, Howell SB (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62:1154-1159 (Pubitemid 35222507)
118. Liu H, Baliga R (2003) Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 63:1687-1696 (Pubitemid 36513314)
119. Liu H, Baliga R (2005) Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol 16:1985-1992 (Pubitemid 41716429)
120. Liu H, Baliga M, Baliga R (2002) Effect of cytochrome P450 2E1 inhibitors on cisplatin-induced cytotoxicity to renal proximal tubular epithelial cells. Anticancer Res 22:863-868 (Pubitemid 34475241)
121. Lopez-Novoa JM (1999) Potential role of platelet activating factor in acute renal failure. Kidney Int 55:1672-1682 (Pubitemid 29197954)
122. Losonczy G, Mathe C, Muller V, Szondy K, Moldvay J (2010) Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer. Magy Onkol 54:289-296
123. Ludwig T, Riethmuller C, Gekle M, Schwerdt G, Oberleithner H (2004) Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int 66:196-202 (Pubitemid 38870095)
124. Luke DR, Vadiei K, Lopez-Berestein G (1992) Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 7:1-7
125. Lynch ED, Gu R, Pierce C, Kil J (2005) Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 201:81-89 (Pubitemid 40255547)
126. Masereeuw R, Terlouw SA, van Aubel RA, Russel FG, Miller DS (2000) Endothelin B receptor-mediated regulation of ATPdriven drug secretion in renal proximal tubule. Mol Pharmacol 57:59-67 (Pubitemid 30033260)
127. Matsushima H, Yonemura K, Ohishi K, Hishida A (1998) The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 131:518-526 (Pubitemid 28278570)
128. Milner LS, Wei SH, Houser MT (1993) Enhancement of renal and hepatic glutathione metabolism by dimethylthiourea. Toxicol Lett 66:117-123
129. Mishima K, Baba A, Matsuo M, Itoh Y, Oishi R (2006) Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med 40:1564-1577
130. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J (2000) Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403:98-103 (Pubitemid 30038529)
131. Nick JA, Avdi NJ, Young SK, Lehman LA, McDonald PP, Frasch SC, Billstrom MA, Henson PM, Johnson GL, Worthen GS (1999) Selective activation and functional significance of p38alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. J Clin Invest 103:851-858 (Pubitemid 29152631)
132. Norbury CJ, Zhivotovsky B (2004) DNA damage-induced apoptosis. Oncogene 23:2797-2808 (Pubitemid 38638843)
133. Old LJ (1988) Tumor necrosis factor. Sci Am 258(59-60):69-75
134. Olivero OA, Chang PK, Lopez-Larraza DM, Semino-Mora MC, Poirier MC (1997) Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat Res 391:79-86 (Pubitemid 27263454)
135. Ormstad K, Uehara N (1982) Renal transport and disposition of Na-2- mercaptoethane sulfonate disulfide (dimesna) in the rat. FEBS Lett 150:354-358 (Pubitemid 13184074)
136. Ozen S, Akyol O, Iraz M, Sogut S, Ozugurlu F, Ozyurt H, Odaci E, Yildirim Z (2004) Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats. J Appl Toxicol 24:27-35 (Pubitemid 38185778)
137. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994-1007 (Pubitemid 351543900)
138. Pabla N, Murphy RF, Liu K, Dong Z (2009) The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296:F505-F511
139. Pabla N, Dong G, Jiang M, Huang S, Kumar MV, Messing RO, Dong Z (2011) Inhibition of PKCdelta reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest 121:2709-2722
140. Park MS, De Leon M, Devarajan P (2002) Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 13:858-865 (Pubitemid 34274081)
141. Petrosillo G, Ruggiero FM, Paradies G (2003) Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. FASEB J 17:2202-2208 (Pubitemid 37509576)
142. Peyrou M, Hanna PE, Cribb AE (2007) Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol Sci 99:346-353 (Pubitemid 47250391)
143. Pirotzky E, Guilmard C, Sidoti C, Ivanow F, Principe P, Braquet P (1990) Platelet-activating factor antagonist, BN-52021 protects against cis-diamminedichloroplatinum nephrotoxicity in the rat. Ren Fail 12:171-176
144. Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835-842
145. Ramesh G, Reeves WB (2003) TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610-F618 (Pubitemid 37140245)
146. Ramesh G, Reeves WB (2005) p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289:F166-F174 (Pubitemid 40863584)
147. Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368-379 (Pubitemid 17235084)
148. Rjiba-Touati K, Ayed-Boussema I, Bouaziz C, Belarbia A, Azzabi A, Achour A, Hassen W, Bacha H (2012) Protective effect of erythropoietin against cisplatin-induced nephrotoxicity in rats: antigenotoxic and antiapoptotic effect. Drug Chem Toxicol 35:89-95
149. Rodrigues MA, Rodrigues JL, Martins NM, Barbosa F, Curti C, Santos NA, Santos AC (2010) Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats. Mitochondrion 10:46-53
150. Rodrigues MA, Rodrigues JL, Martins NM, Barbosa F, Curti C, Santos NA, Santos AC (2011) Carvedilol protects against cisplatininduced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chem Biol Interact 189:45-51
151. Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55:2303-2306
152. Rosenberg B, Vancamp L, Krigas T (1965) Inhibition of cell division in Escherichia Coli by electrolysis products from a platinum electrode. Nature 205:698-699
153. Rosenberg B, Renshaw E, Vancamp L, Hartwick J, Drobnik J (1967) Platinum-induced filamentous growth in Escherichia coli. J Bacteriol 93:716-721
154. Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385-386
155. Sadzuka Y, Shoji T, Takino Y (1992) Mechanism of the increase in lipid peroxide induced by cisplatin in the kidneys of rats. Toxicol Lett 62:293-300
156. Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM (2009) Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 55:399-406
157. Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Lopez-Novoa JM, Morales AI (2011a) An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol 41:803-821
158. Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, Morales AI, Lopez-Novoa JM (2011b) Quercetin reduces cisplatin nephrotoxicity in rats without compromising its antitumour activity. Nephrol Dial Transplant 26:3484-3495
159. Santos NA (2012) Oxidants and inhibition of cisplatin-induced kidney injury: role of mitochondria. In: Spitz DR (ed) Oxidative Stress in Cancer Biology and Therapy, 1st edn. Springer, New York, pp 407-425
160. Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC (2007) Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 81:495-504 (Pubitemid 47012464)
161. Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC (2008) Hydroxyl radical scavenger ameliorates cisplatininduced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 61:145-155 (Pubitemid 47512636)
162. Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV (2003) Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52:13-18 (Pubitemid 36920623)
163. Sastry J, Kellie SJ (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22:441-445 (Pubitemid 40993608)
164. Satoh M, Kashihara N, Fujimoto S, Horike H, Tokura T, Namikoshi T, Sasaki T, Makino H (2003) A novel free radical scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo. J Pharmacol Exp Ther 305:1183-1190 (Pubitemid 36617997)
165. Schenellmann RG (2001) Toxic responses of the kidney. In: Kalassen CD (ed) Casarett and Doull's toxicology. The basic science of poisons, 6th edn. McGraw-Hill, New York, pp 491-514
166. Schmalhausen EV, Zhlobek EB, Shalova IN, Firuzi O, Saso L, Muronetz VI (2007) Antioxidant and prooxidant effects of quercetin on glyceraldehyde-3- phosphate dehydrogenase. Food Chem Toxicol 45:1988-1993 (Pubitemid 47238214)
167. Schrier RW, Chen YC, Cadnapaphornchai MA (2004) From finch to fish to man: role of aquaporins in body fluid and brain water regulation. Neuroscience 129:897-904 (Pubitemid 39556242)
168. Sergediene E, Jonsson K, Szymusiak H, Tyrakowska B, Rietjens IM, Cenas N (1999) Prooxidant toxicity of polyphenolic antioxidants to HL-60 cells: description of quantitative structure-activity relationships. FEBS Lett 462:392-396
169. Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot- Leclercq MP (2008) Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis 13:11-32
170. Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP (2005) p53- dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem 280:31230-31239 (Pubitemid 41291860)
171. Sharma H, Sen S, Singh N (2005) Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 4:949-955 (Pubitemid 41598589)
172. Sharp PA (2003) Ctr1 and its role in body copper homeostasis. Int J Biochem Cell Biol 35:288-291 (Pubitemid 36084449)
173. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821 (Pubitemid 27366733)
174. Sleijfer DT, Offerman JJ, Mulder NH, Verweij M, van der Hem GK, Schraffordt Koops HS, Meijer S (1987) The protective potential of the combination of verapamil and cimetidine on cisplatininduced nephrotoxicity in man. Cancer 60:2823-2828 (Pubitemid 17161819)
175. Somani SM, Husain K, Whitworth C, Trammell GL, Malafa M, Rybak LP (2000) Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol Toxicol 86:234-241 (Pubitemid 30333651)
176. Strasser A, O'Connor L, Dixit VM (2000) Apoptosis signaling. Annu Rev Biochem 69:217-245
177. Szlosarek PW, Balkwill FR (2003) Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4:565-573 (Pubitemid 38351714)
178. Tanihara Y, Masuda S, Katsura T, Inui K (2009) Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol 78:1263-1271
179. Tarladacalisir YT, Kanter M, Uygun M (2008) Protective effects of vitamin C on cisplatin-induced renal damage: a light and electron microscopic study. Ren Fail 30:1-8
180. Tirosh O, Katzhendler Y, Barenholz Y, Ginsburg I, Kohen R (1996) Antioxidant properties of amidothionophosphates: novel antioxidant molecules. Free Radic Biol Med 20:421-432 (Pubitemid 26077865)
181. Togna GI, Togna AR, Franconi M, Caprino L (2000) Cisplatin triggers platelet activation. Thromb Res 99:503-509
182. Townsend DM, Hanigan MH (2002) Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300:142-148 (Pubitemid 34028520)
183. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1-10 (Pubitemid 36026291)
184. Treskes M, Nijtmans LG, Fichtinger-Schepman AM, van der Vijgh WJ (1992) Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43:1013-1019
185. Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M (2003) Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 63:72-82 (Pubitemid 35463908)
186. Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552:335-344 (Pubitemid 37321833)
187. Ueda N, Kaushal GP, Shah SV (2000) Apoptotic mechanisms in acute renal failure. Am J Med 108:403-415 (Pubitemid 30162959)
188. Vondalova Blanarova O, Jelinkova I, Szoor A, Skender B, Soucek K, Horvath V, Vaculova A, Andera L, Sova P, Szollosi J, Hofmanova J, Vereb G, Kozubik A (2011) Cisplatin and a potent platinum(IV) complex-mediated enhancement of TRAILinduced cancer cells killing is associated with modulation of upstream events in the extrinsic apoptotic pathway. Carcinogenesis 32:42-51
189. Wainford RD, Weaver RJ, Stewart KN, Brown P, Hawksworth GM (2008) Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology 249:184-193
190. Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628-8633 (Pubitemid 38019198)
191. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320 (Pubitemid 41130944)
192. Ward JP (1975) Gamma-glutamyl transpeptidase. A sensitive indicator of renal ischaemic injury in experimental animals and renal homograft rejection in man. Ann R Coll Surg Engl 57:248-261
193. Wei Q, Dong G, Franklin J, Dong Z (2007a) The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72:53-62 (Pubitemid 47014446)
194. Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z (2007b) Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 293:F1282-F1291 (Pubitemid 47583963)
195. Werner M, Costa MJ, Mitchell LG, Nayar R (1995) Nephrotoxicity of xenobiotics. Clin Chim Acta 237:107-154
196. Winston JA, Safirstein R (1985) Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 249:F490-F496 (Pubitemid 16185880)
197. Wong E, Giandomenico CM (1999) Current status of platinum-based antitumor drugs. Chem Rev 99:2451-2466
198. Wu XX, Kakehi Y (2009) Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspasedependent manner. Clin Cancer Res 15:2039-2047
199. Wu YJ, Muldoon LL, Neuwelt EA (2005) The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312:424-431 (Pubitemid 40189538)
200. Yamakawa T, Eguchi S, Matsumoto T, Yamakawa Y, Numaguchi K, Miyata I, Reynolds CM, Motley ED, Inagami T (1999) Intracellular signaling in rat cultured vascular smooth muscle cells: roles of nuclear factor-kappaB and p38 mitogen-activated protein kinase on tumor necrosis factor-alpha production. Endocrinology 140:3562-3572 (Pubitemid 30645410)
201. Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ (2006) Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 12:5817-5825 (Pubitemid 44629614)
202. Yang C, Kaushal V, Haun RS, Seth R, Shah SV, Kaushal GP (2008) Transcriptional activation of caspase-6 and -7 genes by cisplatininduced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ 15:530-544 (Pubitemid 351267304)
203. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115-124 (Pubitemid 47262919)
204. Yee MS, Blakley BW, Begleiter A, Leith M (2008) Delayed sodium thiosulphate administration reduces cisplatin efficacy on mouse EMT6 tumour cells in vitro. J Otolaryngol Head Neck Surg 37:638-641
205. Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K (2005) Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70:1823-1831 (Pubitemid 41612013)
206. Zhang L, Hanigan MH (2003) Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J Pharmacol Exp Ther 306:988-994 (Pubitemid 37025305)